['type 2 diabetes mellitus']
['insulin glargine/ lixisenatide fixed-ratio combination hoe901/ave0010', 'insulin glargine hoe901', 'placebo']

        Inclusion criteria :

          -  Japanese male or female patients with T2DM diagnosed for at least 1 year prior to the
             time of screening as established in the medical history.

          -  Patients aged 20 to 75 years at screening.

          -  Body mass index ≤35 kg/m^2 at screening.

          -  Glycohemoglobin ≥7.0% and ≤10.0% at screening.

          -  Fasting C-peptide ≥0.6 ng/mL at screening.

        Exclusion criteria:

          -  Diabetes other than T2DM.

          -  History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to
             screening.

          -  History of hypoglycemia unawareness.

          -  Hemoglobinopathy or hemolytic anemia.

          -  History of myocardial infarction, stroke, or heart failure, history or presence of
             clinically significant diabetic retinopathy, history or presence of macular edema
             likely to require laser treatment within the study period.

          -  History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy,
             stomach/gastric surgery, inflammatory bowel disease.

          -  Clinically relevant history of gastrointestinal disease associated with prolonged
             nausea and vomiting, including, but not limited to gastroparesis and gastroesophageal
             reflux disease requiring medical treatment.

          -  Personal or family history of medullary thyroid cancer (MTC) or genetic conditions
             that predispose to MTC (e.g., multiple endocrine neoplasia syndromes).

          -  If female, pregnancy or breast-feeding.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      